肝炎对弥漫性大B细胞淋巴瘤患者总生存期和无进展生存期的负面影响。
Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma.
作者信息
Al-Mansour Mubarak M, Alghamdi Saif A, Alsubaie Musab A, Alesa Abdullah A, Khan Muhammad A
机构信息
Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region (WR), PO Box 9515, Jeddah, 21423 Kingdom of Saudi Arabia.
2College of Medicine (COM), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah, Saudi Arabia.
出版信息
Infect Agent Cancer. 2018 Jun 7;13:18. doi: 10.1186/s13027-018-0190-9. eCollection 2018.
BACKGROUND
Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy.
METHODS
This retrospective cohort study was conducted at Princess Noorah Oncology Center, Jeddah by reviewing all medical records of 172 DLBCL diagnosed patients and recieved Rituximab-containing chemotherapy dated from January 2009 to February 2016.
RESULTS
Out of 172 patients, 53 were found positive in hepatitis serology. The 12 of those were HBsAg-positive and 41 were HBcAb-positive. Hepatitis reactivation was observed in 1% of the patients (i.e., 2 out of 172) and both of them were HBsAg-positive. Thus, the risk of hepatitis reactivation among the HBsAg-positive patients was 17% (i.e., 2 out of 12). The predicted 3-year PFS for HBsAg-positive and HBcAb-positive were 52% (± 8%), while 76% (± 4) for HBsAg-negative and HBcAb-negative patients. On the other hand, the predicted 3-year OS for HBsAg and HBcAb-negative group is 93% (±3) while for HBsAg-positive and HBcAb-positive is 77% (±7), respectively.
CONCLUSION
The present study demonstrated a low HBV reactivation rate of 1% exclusively in 2 patients with HBsAg-positive status diagnosed with DLBCL and receiving R-CHOP chemotherapy.
背景
乙型肝炎病毒（HBV）是全球最普遍且严重的感染之一。HBV再激活是接受含利妥昔单抗方案治疗的淋巴瘤患者的严重并发症。由于HBV对弥漫性大B细胞淋巴瘤（DLBCL）预后的影响尚未得到充分评估，本研究探讨了肝炎感染对接受含利妥昔单抗化疗的DLBCL患者无进展生存期（PFS）和总生存期（OS）的影响。
方法
本回顾性队列研究在吉达的努拉公主肿瘤中心进行，回顾了2009年1月至2016年2月期间诊断为DLBCL并接受含利妥昔单抗化疗的172例患者的所有病历。
结果
172例患者中，53例肝炎血清学检查呈阳性。其中12例HBsAg阳性，41例HBcAb阳性。1%的患者（即172例中的2例）出现肝炎再激活，且均为HBsAg阳性。因此，HBsAg阳性患者中肝炎再激活的风险为17%（即12例中的2例）。HBsAg阳性和HBcAb阳性患者的预测3年PFS为52%（±8%），而HBsAg阴性和HBcAb阴性患者为76%（±4%）。另一方面，HBsAg和HBcAb阴性组的预测3年OS为93%（±3%），而HBsAg阳性和HBcAb阳性组分别为77%（±7%）。
结论
本研究表明，在诊断为DLBCL并接受R-CHOP化疗的2例HBsAg阳性患者中，HBV再激活率低至1%。
Zotero 插件